Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
Status:
Completed
Trial end date:
2020-12-09
Target enrollment:
Participant gender:
Summary
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events
in patients with coronary artery disease, but these benefits come at the expense of increased
risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12
inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk
compared with DAPT. Therefore, the investigators performed this study to observe the efficacy
of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University